175 related articles for article (PubMed ID: 16622993)
1. Outcome of pediatric hematopoietic stem cell transplantations from Thai unrelated donors matched with high-resolution HLA typing.
Vanichsetakul P; O-Charoen R; Seksarn P; Kupatawintu P
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S1-6. PubMed ID: 16622993
[TBL] [Abstract][Full Text] [Related]
2. Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing.
Giebel S; Giorgiani G; Martinetti M; Zecca M; Maccario R; Salvaneschi L; Holowiecki J; Locatelli F
Bone Marrow Transplant; 2003 Jun; 31(11):987-93. PubMed ID: 12774049
[TBL] [Abstract][Full Text] [Related]
3. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
4. Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study.
Hauzenberger D; Schaffer M; Ringdén O; Hassan Z; Omazic B; Mattsson J; Wikström AC; Remberger M
Tissue Antigens; 2008 Dec; 72(6):549-58. PubMed ID: 19000143
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China.
Liu QF; Xu XJ; Chen YK; Sun J; Zhang Y; Fan ZP; Xu D; Jiang QL; Wei YQ; Huang F; Feng R; Liu XL; Xu B; Meng FY
Ann Hematol; 2011 Mar; 90(3):331-41. PubMed ID: 20872002
[TBL] [Abstract][Full Text] [Related]
6. Unrelated cord blood transplant experience by the pediatric blood and marrow transplant consortium.
Yu LC; Wall DA; Sandler E; Chan KW; Grayson G; Kletzel M
Pediatr Hematol Oncol; 2001 Jun; 18(4):235-45. PubMed ID: 11400647
[TBL] [Abstract][Full Text] [Related]
7. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
8. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors.
Greinix HT; Faé I; Schneider B; Rosenmayr A; Mitterschiffthaler A; Pelzmann B; Kalhs P; Lechner K; Mayr WR; Fischer GF
Bone Marrow Transplant; 2005 Jan; 35(1):57-62. PubMed ID: 15531903
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
10. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.
Yanada M; Emi N; Naoe T; Sakamaki H; Takahashi S; Hirabayashi N; Hiraoka A; Kanda Y; Tanosaki R; Okamoto S; Iwato K; Atsuta Y; Hamajima N; Tanimoto M; Kato S
Bone Marrow Transplant; 2004 Aug; 34(4):331-7. PubMed ID: 15220958
[TBL] [Abstract][Full Text] [Related]
12. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources.
Souillet G; Guffon N; Maire I; Pujol M; Taylor P; Sevin F; Bleyzac N; Mulier C; Durin A; Kebaili K; Galambrun C; Bertrand Y; Froissart R; Dorche C; Gebuhrer L; Garin C; Berard J; Guibaud P
Bone Marrow Transplant; 2003 Jun; 31(12):1105-17. PubMed ID: 12796790
[TBL] [Abstract][Full Text] [Related]
13. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.
Remberger M; Naseh N; Aschan J; Barkholt L; LeBlanc K; Svennberg P; Ringdén O
Bone Marrow Transplant; 2003 Jul; 32(2):217-23. PubMed ID: 12838288
[TBL] [Abstract][Full Text] [Related]
14. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients.
Kurtzberg J; Laughlin M; Graham ML; Smith C; Olson JF; Halperin EC; Ciocci G; Carrier C; Stevens CE; Rubinstein P
N Engl J Med; 1996 Jul; 335(3):157-66. PubMed ID: 8657213
[TBL] [Abstract][Full Text] [Related]
15. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin.
Sedlácek P; Formánková R; Keslová P; Srámková L; Hubácek P; Król L; Kulich M; Starý J
Bone Marrow Transplant; 2006 Dec; 38(11):745-50. PubMed ID: 17041606
[TBL] [Abstract][Full Text] [Related]
16. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
17. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of 66 cases received hematopoietic stem cell transplantation from unrelated donors].
Chen YH; Huang XJ; Chen H; Xu LP; Liu DH; Jiang Q; Zhang YC; Han W; Gao ZY; Wang JZ; Liu KY; Wu T; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):656-60. PubMed ID: 16620550
[TBL] [Abstract][Full Text] [Related]
20. Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation.
Tamouza R; Busson M; Rocha V; Fortier C; Haddad Y; Brun M; Boukouaci W; Bleux H; Socié G; Krishnamoorthy R; Toubert A; Gluckman E; Charron D
Transplantation; 2006 Dec; 82(11):1436-40. PubMed ID: 17164714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
